ImmunoCellular Therapeutics Risk Adjusted Performance
| IMUC Stock | | | USD 0.20 0.02 11.11% |
ImmunoCellular Therapeutics risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for ImmunoCellular Therapeutics or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also
Equity Screeners to view more equity screening tools
ImmunoCellular Therapeutics has current Risk Adjusted Performance of 0.1259.
RAP | = | (ER[a] - RFR) * STD[b])/STD[b]RFR |
| = | 0.1259 | |
ImmunoCellular Therapeutics Risk Adjusted Performance Peers Comparison
ImmunoCellular Risk Adjusted Performance Relative To Other Indicators
ImmunoCellular Therapeutics is currently regarded as number one stock in risk adjusted performance category among its peers. It is currently under evaluation in maximum drawdown category among its peers reporting about
1,503 of Maximum Drawdown per Risk Adjusted Performance. The ratio of Maximum Drawdown to Risk Adjusted Performance for ImmunoCellular Therapeutics is roughly
1,503
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.